Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine effects on the EC50 of sufentanil for blunting intubation hemodynamic responses in obese adults
ChiCTR2400085106Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine and sufentanil in obesity (2 arms), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoints: Diastolic blood pressure, Systolic blood pressure and 2 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
dexmedetomidinesufentanil
03
Conditions
obesity
Beyond the preview
Go deeper on ChiCTR2400085106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085106.